Clinical Trials Logo

Clinical Trial Summary

This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective drug that works in patients with relapsed refractory follicular lymphoma. Giving tazemetostat in combination with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05205252
Study type Interventional
Source Epizyme, Inc.
Contact Clinical Trial
Phone 1 (855) 500-1011
Status Recruiting
Phase Phase 1/Phase 2
Start date December 22, 2021
Completion date May 2028

See also
  Status Clinical Trial Phase
Terminated NCT02952573 - Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement Phase 2
Completed NCT03439280 - A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM) Phase 1/Phase 2